NLRP3 Inflammasome Mechanisms in Parkinson's Disease

Parkinson’s disease is characterised by the progressive loss of dopaminergic neurons in the substantia nigra and the accumulation of misfolded α-synuclein aggregates. Central to its pathogenesis is chronic neuroinflammation orchestrated by the NLRP3 inflammasome, a cytosolic multiprotein complex found in microglia and neurons. Activation of NLRP3 proceeds via a priming signal—often through toll-like receptors and NF-κB activation—that upregulates NLRP3 and pro-interleukin-1β, followed by an assembly step triggered by mitochondrial dysfunction, reactive oxygen species or lysosomal damage. Upon assembly, NLRP3 recruits the adaptor ASC and procaspase-1, enabling caspase-1 maturation and subsequent processing of IL-1β and IL-18. The release of these cytokines amplifies inflammatory cascades, exacerbates α-synuclein pathology and perpetuates neuronal injury. Dysregulated NLRP3 activity thus drives a self-sustaining cycle of inflammation and neurodegeneration, underscoring the inflammasome as a pivotal mediator and therapeutic target in Parkinson’s disease.

Research from Nature Portfolio

No recent Nature Portfolio content available.

NLRP3 Inflammasome Mechanisms in Parkinson's Disease publication trend

The graph below shows the total number of articles in nlrp3 inflammasome mechanisms in parkinson's disease across all publications each year (not limited to Nature Index journals).

Technical terms

NLRP3 inflammasome: A cytosolic protein complex that organises caspase-1 activation in response to cellular stress.

Microglia: Resident innate immune cells of the central nervous system that mediate inflammatory processes.

α-Synuclein: A neuronal protein prone to misfolding and aggregation, forming Lewy bodies in Parkinson’s disease.

Caspase-1: An enzyme activated by inflammasomes that cleaves pro-inflammatory cytokines into their mature, secreted forms.

IL-1β: A potent pro-inflammatory cytokine produced upon inflammasome activation, driving neuroinflammation.

Parkin: An E3 ubiquitin ligase mutated in some familial forms of Parkinson’s disease, regulating protein degradation.

References

1. Pharmacologic inhibition of NLRP3 reduces the levels of α-synuclein and protects dopaminergic neurons in a model of Parkinson’s disease. Journal of Neuroinflammation (2023).
2. Parkin regulates microglial NLRP3 and represses neurodegeneration in Parkinson's disease. Aging Cell (2023).
3. Targeting Microglial α-Synuclein/TLRs/NF-kappaB/NLRP3 Inflammasome Axis in Parkinson’s Disease. Frontiers in Immunology (2021).
4. Mitochondrial impairment in microglia amplifies NLRP3 inflammasome proinflammatory signaling in cell culture and animal models of Parkinson’s disease. npj Parkinson's Disease (2017).